甲状腺微小乳头状癌中Galectin-3、CK19和HBME-1的表达及其意义

甲状腺微小乳头状癌中Galectin-3、CK19和HBME-1的表达及其意义

贺家勇1， 付娟娟2, 杨晨晨3

(1中国石油乌鲁木齐石油化工总厂职工医院外一科， 乌鲁木齐830019;2新疆维吾尔自治区人民医院病理科, 乌鲁木齐830000

3新疆医科大学, 乌鲁木齐830011)

摘要：目的探讨甲状腺微小乳头状癌中Galectin-3、CK19和HBME-1的表达及其临床意义。方法采用免疫组化Envision法检测甲状腺微小乳头状癌及甲状腺良性病变伴乳头状增生中Galectin-3、CK19及HBME-1的表达，并分析Galectin-3、CK19及HBME-1与临床病理的关系。结果CK19的表达定位于胞浆中，CK19甲状腺微小乳头状癌和甲状腺良性病变伴乳头状增生中的阳性表达率分别为92.5%(37/40)和10.0%(4/40)，差异有统计学意义。有38例(95.0%)Galectin-3阳性表达，阳性部位定位于细胞膜和细胞质上，呈弥漫性阳性表达。34例(85.0%)样本HBME-1呈中度阳性及强阳性着色，2例(5.0%)呈弱阳性着色，主要在细胞膜及少部分胞质中表达，阳性表达率为90.0%。17例(42.5%)乳头状癌中同时出现CK19、HBME-1及Galectin-3强阳性表达，而良性病变患者未见同时出现CK19、HBME-1及Galectin-3的强阳性表达。甲状腺微小乳头状癌中Galectin-3、CK19及HBME-1的阳性表达率明显高于甲状腺良性病变伴乳头增生，差异有统计学意义。CK19的高表达与性别有关， HBME-1的阳性表达与年龄有关，差异具有统计学意义(P<0.05)。结论CK19、HBME-1及Galectin-3在甲状腺微小癌中的表达明显高于甲状腺良性病变伴乳头状增生，是诊断甲状腺微小乳头状癌的重要标志物，联合检测更能提高甲状腺微小乳头状癌的准确性。

关键词：甲状腺微小乳头状癌； Galectin-3； CK19； HBME-1； 标志物； 免疫组织化学

中图分类号：R736.1文献标识码：A

doi:10.3969/j.issn.1009-5551.2015.07.012

[收稿日期：2015-01-10]

基金项目：新疆医科大学第一附属医院自然青年科学基金(2013ZRQN52)

作者简介：陈兆云(1979-)，男，在读硕士，主管技师，研究方向：临床免疫学检验。

Expression and significance of Galectin-3, CK19 and HBME-1

in papillary thyroid microcarcinoma

He Jiayong1, FU Juanjuan2, YANG Chenchen3

(1DepartmentofSurgery,Staff-workerHospitalofUrumqiPetrochemicalSubsidiary

ChinaNationalPetroleum,Urumqi830019,China;2DepartmentofPathology,ThePeople’s

HospitalofXinjiangUygurAutonomousRegion,Urumqi830000,China;

3XinjiangMedicalUniversity,Urumqi830011,China)

Abstract:ObjectiveTo investigate expression and clinical significance of Galectin-3, CK19 and HBME-1 in papillary thyroid microcarcinoma. MethodsEnvision immunohistochemistry was used to detect the expression of Galectin-3, CK19 and HBME-1 in papillary thyroid microcarcinoma and benign thyroid lesions; and their clinical pathology relationship was analyzed. ResultsThe positive expression rate of CK19 in papillary thyroid microcarcinoma and benign thyroid disease was 92.5%(37/40) and 10.0%(4/40) respectively, and the difference was statistically significant. There were 37 cases (92.5%) showed positive staining of Galectin-3, three cases (7.5%) were weakly positive staining. The positive part was at the cell membrane and cytoplasm, diffuse positive expression. 34(85.0%) cases showed positive staining of HBME-1 and 2 cases (5.0%) were weakly positive staining. The positive expression rate was 90.0%. CK19, HBME-1 and Galectin-3 were all expressed in 17(42.5%) patients with papillary thyroid microcarcinoma, and no simultaneous expression of CK19, HBME-1 and Galectin-3 appeared in patients with benign lesions. The expression of Galectin-3, CK19 and HBME-1 in small papillary thyroid carcinoma was significantly higher than that in benign thyroid lesions with papillary hyperplasia, the difference was statistically significant. High expression of CK19 HBME-1 was related with gender, age, the difference was statistically significant (P<0.05). ConclusionThe expression of CK19, HBME-1 and Galectin-3 in papillary thyroid microcarcinoma was significantly higher than that in benign lesions caused by papillary thyroid hyperplasia. The combined detection of CK19, HBME-1 and Galectin-3 will further improve the accucacy of papillary thyroid microcarcinoma.

Key words: small papillary thyroid carcinoma; Galectin-3; CK19; HBME-1; markers

甲状腺乳头状癌是常见的内分泌系统的恶性肿瘤，近年来其发病率不断升高[1-2]。……